<DOC>
	<DOC>NCT00888576</DOC>
	<brief_summary>The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.</brief_summary>
	<brief_title>Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Main 1) Male or female patients aged &gt; 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main None</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>